Hively Brad

Director Brad Hively sells 1,976,137 shares ($5.7M) at TOI, reducing stake by 76.6% post-transaction holdings drop to 603,501 shares

Brad Hively, a director at Oncology Institute, executed 2 separate sales totaling 1,976,137 shares for $5,672,106.03 at $2.87 per share on 2025-06-03. This sale represents a -76.6% reduction in his holdings, from 2,579,638 shares to 603,501 shares post-transaction. At this ticker specifically, Hively's prior trades show a strong 90-day win rate: his buy on 2024-12-02 returned +468.1% over 90 days, and his buy on 2024-11-26 returned +400.0% over 90 days. The stock is currently trading at $2.79, near 90-day highs in a +289.7% uptrend off the 52-week low. However, the company remains unprofitable with a net loss of $19,585,000 against quarterly revenue of $104,406,000, creating a mismatch between the recent appreciation and underlying fundamentals. The scale and timing of this liquidation, coupled with persistent negative earnings despite revenue growth, merit closer examination of the company's path to profitability.

Director Brad Hively buys 9.1K shares at $1.04; 2 prior TOI buys both +400%+ at 90d, 7-insider cluster

Brad Hively, a Director, purchased 9,056 shares at $1.04 on 2025-03-26, increasing his holdings to 675.8K shares. His timing at this ticker shows a strong pattern: both prior open-market purchases at TOI (on 2024-12-02 and 2024-11-26) delivered 90-day returns of +468.1% and +400.0% respectively, indicating well-timed entries into strong rallies. The current transaction occurs as the stock trades at $1.14, representing a +19.2% 30-day gain and +260.2% 90-day gain from the purchase date. A cluster of 7 other insiders also bought within the past 14 days, suggesting coordinated conviction among the board. Notably, the company reported a net loss of $16.1M on $99.9M revenue in its most recent quarter, so this buying occurs amid unprofitability, raising the question of whether insiders see a turnaround catalyst or are backing a distressed situation.

Director Hively Brad bought 300,000 shares of TOI across 2 transactions for $50,000.00, boosting stake 81.8% amid -93.0% stock decline from 52-week high.

Director Brad Hively purchased 300,000 shares across 2 separate transactions on 2024-11-26 and 2024-12-02, at blended average price of $0.17 per share ($50,000.00 total), expanding his holdings from 366,753 shares to 666,753 shares. The timing of these purchases follows steep recent price declines—the stock trades at $0.16 today, down 93.0% from its 52-week high of $2.30 and down 46.6% over the past 30 days. While the company generated Revenue $99,901,000.00 in the latest quarter with strong 28.4% annual revenue growth, it remains deeply unprofitable with Net income $-16,113,000.00 and a minimal market cap of $12,089,452.00. The substantial share accumulation at depressed prices by a sitting director warrants attention to the underlying rationale—whether this reflects confidence in a turnaround or other motivations—particularly given the company's ongoing losses and the extreme valuation compression in the equity.